-
1 Comment
Khiron Life Sciences Corp is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.6.
Khiron Life Sciences Corp's total revenue sank by 30.5% to $2M since the same quarter in the previous year.
Its net income has increased by 36.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 38.8% to $-5M since the same quarter in the previous year.
Based on the above factors, Khiron Life Sciences Corp gets an overall score of 3/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | CA49374L3065 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 6M |
---|---|
PE Ratio | None |
Target Price | None |
Dividend Yield | 0.0% |
Beta | 3.15 |
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4KH.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025